Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1247
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 925–936 of 1,247 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

Mechanisms of Diuretic Resistance in Heart Failure, Aim 1

NCT05323487
Status at this site: Recruiting
Conditions
Heart Failure
Interventions
Bumetanide Injection
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Saci Nivo Rela for TNBC

NCT06963905
Status at this site: Recruiting
Conditions
Metastatic Triple-negative Breast Cancer
Interventions
Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting Phase 2 Interventional

Substance Misuse and Family Violence Treatment Fathers

NCT06650267
Status at this site: Recruiting
Conditions
Substance Misuse, Violence, Domestic, Child Abuse
Interventions
Fathers for Change (F4C), Individual Drug Counseling (IDC)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Conditions
Small Cell Lung Cancer
Interventions
YL201, Tarlatamab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Irvine, California • New Haven, Connecticut • Tampa, Florida + 7 more
Recruiting No phase listed Observational

A Registry for People With T-cell Lymphoma

NCT05978141
Status at this site: Not yet recruiting
Conditions
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Interventions
Optional Blood Sample and Nail Sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
26
States / cities
Duarte, California • San Diego, California • San Francisco, California + 20 more
Conditions
Critical Illness, Sleep Deprivation, Circadian Rhythm Sleep Disorder, Unspecified
Interventions
Chronobundle - light, chronobundle - feeding, chronobundle - mobility, chronobundle - sleep
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Recruiting Not applicable Interventional

Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition

NCT06094478
Status at this site: Recruiting
Conditions
Stroke, Acute, Ischemic Stroke, Acute, Hemorrhagic Stroke
Interventions
HI-SPEED Protocol
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
New Haven, Connecticut • Miami, Florida • Atlanta, Georgia + 5 more
Recruiting No phase listed Observational

An Evaluation of Hip Preservation Outcomes

NCT05746533
Status at this site: Recruiting
Conditions
Hip Arthroscopy, Femoroacetabular Impingement
Interventions
Hip Arthroscopy
Procedure
Lead sponsor
Yale University
Other
Eligibility
12 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2053
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
Status at this site: Recruiting
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Peer Support in the ED (PCORI)

NCT06556069
Site status not listed — check the official record
Conditions
Psychomotor Agitation, Behavioral Disorder
Interventions
Peer-Support Enhanced Agitation Code Team (PACT)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
57,870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Interventions
Assessment of Therapy Complications, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Active, not recruiting Not applicable Interventional

MitraClip REPAIR MR Study

NCT04198870
Site status not listed — check the official record
Conditions
Mitral Valve Regurgitation
Interventions
MitraClip™ device implantation, Mitral Valve Repair Surgery
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
63
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 47 more

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.